SY49 - Bouncing Back From Denosumab Discontinuation

Symposium Chair(s)

• WC

  Weiwen Chen

  Disclosure information not submitted.
• 

  Christian Girgis, MBBS PhD FRACP (he/him/his)

  UNIVERSITY OF SYDNEY
  Sydney, Australia

  Disclosure(s): Theramex: Advisory Board ()

This session characterizes the clinical problem of post-denosumab bone loss, provides a comprehensive update on human studies examining the use of bisphosphonates following denosumab and explores mechanistic insights from preclinical studies that will be critical in the design of definitive human trials

Presentations:

• 10:30 AM - 11:00 AM CT

  Discontinuation of Denosumab: Bone Loss and Vertebral Fractures: Risk Factors and Red Flags
  

  Symposium Speaker: MARIAN SCHINI, MD, PhD (she/her/hers) – UNIVERSITY OF SHEFFIELD
• 11:00 AM - 11:30 AM CT

  Understanding the Pathophysiology of the Post-Denosumab Overshoot: Mechanistic Insights
  

  Symposium Speaker: Albert S. Kim, MBBS PhD (he/him/his)
• 11:30 AM - 12:00 PM CT

  Strategies to Mitigate Bone Loss After Denosumab Cessation – Current and Future Perspectives
  

  Symposium Speaker: Bente Langdahl, MD, PhD, DMSc – Aarhus University Hospital